Atractylenolide II Suppresses Glycolysis and Induces Apopto-sis by Blocking the PADI3-ERK Signaling Pathway in Endo-metrial Cancer Cells
Atractylenolide II (AT-II), the major bioactive compound of Atractylodes macrocephala exhibits anticancer activity against many types of tumors, but the roles and the potential mechanisms in endometrial cancer remain unclear. To explore a novel therapeutic target of AT-II for the clinical therapy of endometrial cancer,  the high-throughput sequence was performed. Overall design: The RL95-2 cells were treated with AT-II or DMSO for 48h. RNA was extracted using TRIzol reagent, and the samples were sent to Genechem (Shanghai, China) for RNA-seq. Three samples were supplied in each group. The differential ex-pressed genes (DEGs) were defined based on the following criteria: |log2FoldChange| > 1 and p < 0.05.